Sutidiazine
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Sutidiazine
- Molecular weight
- 465.58
- Structure (SMILES)
- Cc1nc(Nc2ncc(N3CCN(C)[C@H](C)C3)c(Nc3cc(C)n(C)n3)n2)cc(C2CC2)c1F
- mmv 253
- Mmv-253
- mmv253
- MMV253
- sutidiazina
- Sutidiazina
- sutidiazine
- Sutidiazine
- sutidiazine [INN]
- sutidiazine inn
- zy 19489
- zy 19489 capsule arm 1
- Zy-19489
- zy19489
- ZY19489
- zy19489 capsule
- ZY19489 Capsule
- CAS registry numbers
- 1821293-40-6
- ChEMBL ID
- CHEMBL4284447
- InChIKey
- HKPQFVAUXAZCDY-OAHLLOKOSA-N
- PubChem compound IDs
- 92045019
- FDA ingredient codes (UNII)
- VL8W9427Y4
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- sutidiazine
- Type
- Synthetic organic
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005920
- Highest recorded phase
- 1
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 2
- Polar surface area
- 87.03
- Calculated partition coefficient (ALogP)
- 3.87
- Calculated partition coefficient (XLogP)
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 34
- Molecular formula
- C24H32FN9
- Monoisotopic mass
- 465.27647022
- Natural product
- No
- Recorded assays
- 11
- Active assays
- 3
Active assay types
- Confirmatory
Cardiac potassium channel inhibition
- Median
- 33,000
- Mean
- 33,000
- Minimum
- 33,000
- Maximum
- 33,000
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Oral bioavailability
- Median
- 80
- Mean
- 80
- Minimum
- 80
- Maximum
- 80
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (36)
- A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
- A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer
- A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
- A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects
- A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain
- A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion
- A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
- Acetaminophen Transfer Across the Placenta and the Assessment of Fetal Well-being
- Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
- Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis
- Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
- Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
- Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication
- Dolutegravir + Rilpivirine Switch Study (DORISS)
- Efficacy of Oral Serratiopaptidase Vs Dexamethasone on Post-Operative Inflammation After Exodontia. An Experience at Tertiary Care Hospital Karachi Pakistan.
- Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
- Hydrocortisone in the Treatment of Intrusions in Patients With Posttraumatic Stress Disorder
- Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial
In development for (1)
- Neoplasm Phase 2